NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/23/2026
Back to search
Official data from USPTO
QUIAPEG PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
04/24/2026
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
09/02/2019
Registration date
09/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2022
Last transaction
04/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
SE
Examiner
CROWLEY, SEAN MICHAEL
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "QUIAPEG" in blue and "PHARMACEUTICALS" in orange and the design a blue hexagon containing three diagonal blue lines with a wavy orange line emanating from its center. The white in the drawing represents background and is not part of the mark.
Holders and representatives
Holders
QuiaPEG Pharmaceuticals AB
Representatives
Cynthia Johnson Walden Fish & Richardson P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Regents for use in industry and sciencereagents for use with a drug delivery system comprising phosphotriester linkers for the controlled release of a wide variety of therapeutic agents; cross linking agents being industrial chemicals for use in industry and science; polyethylene glycols for use in industry and science; chemical structures being industrial chemicalsphosphotriester linkers
Class 5
Pharmaceuticalsmedical and veterinary preparations for the treatment of cancercardiovascular diseaserespiratory disordersmetabolic disordersautoimmune diseaseneurologic and psychiatric disorders and infectious disease derived from PEGylation technologies; pharmaceutical preparationsa drug delivery system comprising phosphotriester linkers for the controlled release of a wide variety of therapeutic agents; pharmaceuticalmedical and veterinary substances
Class 42
Scientific and technological servicesscientific researchanalysistesting and development in the field of pharmaceuticalsof pharmaceuticalmedical and veterinary preparations and substances derived from PEGylation technologies; PEGylation pharmaceuticals research services
Publications
History of USPTO decisions and trademark events.
47 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/06/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/18/2023
FIMP
FINAL DISPOSITION PROCESSED
01/18/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/27/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/27/2022
GPNX
NOTIFICATION PROCESSED BY IB
07/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/12/2022
PUBO
PUBLISHED FOR OPPOSITION
07/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/22/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/22/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/22/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
06/03/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/03/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
06/03/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/03/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/10/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/21/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/21/2021
ATRV
ATTORNEY REVIEW COMPLETED
09/01/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
08/04/2020
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
08/04/2020
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/17/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
07/14/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
07/01/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/01/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
07/01/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/28/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/28/2020
ALIE
ASSIGNED TO LIE
05/28/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/21/2020
RFNT
REFUSAL PROCESSED BY IB
03/07/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/14/2020
RFRR
REFUSAL PROCESSED BY MPU
02/14/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/22/2020
CNRT
NON-FINAL ACTION WRITTEN
01/21/2020
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
12/05/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/05/2019
CNRT
NON-FINAL ACTION WRITTEN
12/04/2019
DOCK
ASSIGNED TO EXAMINER
12/04/2019
MAFR
APPLICATION FILING RECEIPT MAILED
11/29/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/25/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/21/2019
Continuous trademark protection
Get notified about every new filing that threatens QUIAPEG PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.